ArticleClinical Medicine Insights. Oncology2026
A Clinicopathology and Simplified Molecular Marker-Based Risk Stratification Model for Predicting 3-Year Recurrence in Endometrial Cancer.
Article in Clinical Medicine Insights. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MUC16 promotes endometrial cancer progression and modulates sensitivity to lapatinib through the ESR1/PI3K/AKT axis.Translational oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The integration of clinicopathological parameters and molecular biomarkers holds significant prognostic value for endometrial carcinoma (EC) recurrence assessment. The purpose of this study is to combine clinical pathological parameters with simple molecular features to predict 3-year recurrence of EC. Methods: Based on a retrospective cohort with 136 patients assessing recurrence risk within 3 years postoperatively, we developed PM-TERR (clinicopathology and simplified molecular markers-based EC tailored 3-year recurrence risk). All patients were randomly assigned to the training set (96 patients) and the test set (40 patients). The nomogram comprised 4 input variables (Stage, Grade, Pathology Type, and P53 status) for calculating a PM-TERR score. Results: Kaplan-Meier analysis demonstrated a significant association between PM-TERR scores and disease-free survival (DFS) in both the training and test sets (both Conclusion: In summary, the PM-TERR model integrates stage, grade, histology, and p53 status to predict 3-year recurrence risk. This retrospective, single-center study demonstrates its potential utility; however, future prospective, multi-center validation is required to confirm its robustness and clinical applicability before broader implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.